MNKD Mannkind Earnings and EPS analysis

Relative Growth: Rel. Growth: 85

Relative Strength: Rel. Strength: 76

Relative Valuation: Rel. Valuation: 43

Relative Profitability: Rel. Profitability: 71

EPS in 2025 (TTM): $0.11

Last Report Period Date: Jun 30, 2025

Based on the company's latest reports for June 2025, the current 12-month EPS is $0.11. Mannkind's earnings per share in 2024 was reported at $0.1, marking a rise from -$0.04 in 2023. In the quarterly report ending on Jun 30, 2025, MNKD's earnings per share amounted to $0.

MNKD earnings history

Historical annual and quarterly earnings per share (EPS) data for Mannkind

EPS (TTM)

$0.11

EPS Growth YoY (Quarterly)

100%

EPS (Quarterly)

EPS Growth (Quarterly)

-100%

Mannkind had an yealy earnings per share of $0.1, showing a rise of 350% from -$0.04 recorded in 2023. The quarterly earnings per share for the period ending Jun 30, 2025, was $0, showing a 100% increase compared to the same quarter last year. The trailing twelve months EPS for MNKD is $0.11 as of June 2025. Mannkind's full-year EPS for 2023 was -$0.04, a 88.2% rise compared to the previous year.

MNKD EPS growth

Earnings per share growth rates over time

EPS Growth YoY (Quarterly)

100%

EPS growth YoY

350%

EPS growth 3Y avg

N/A

EPS growth 5Y avg

N/A

Mannkind has recorded a growth in earnings per share of 100% in the past 12 months (YoY, quarterly).

MNKD Earnings Waterfall

Breakdown of revenue, profit and net income for Mannkind

MNKD Earnings vs Peers

What are the earnings of MNKD compared to its peers

Stock name	Price to Earnings	EPS grwoth 1Y	EPS grwoth 3Y	EPS grwoth 5Y
MRK Merck & Co Inc	13.15	4,728.6%	9.4%	12%
HALO Halozyme Therapeutics Inc	14.31	64.3%	7%	N/A
PFE Pfizer Inc	14.44	273.7%	-28.7%	-13.2%
LLY ELI LILLY & Co	45.44	102.1%	24.1%	5.7%
MNKD Mannkind Corp	52.91	350%	N/A	N/A
NKTR Nektar Therapeutics	N/A	60%	N/A	N/A

All data is based on quarterly TTM periods, unless otherwise specified.